Natural killer cell-based immunotherapy in gynecologic malignancy: A review

Locke D Uppendahl, Carly M. Dahl, Jeffrey S Miller, Martin Felices, Melissa A Geller

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Harnessing the immune system has proven an effective therapy in treating malignancies. Since the discovery of natural killer (NK) cells, strategies aimed to manipulate and augment their effector function against cancer have been the subject of intense research. Recent progress in the immunobiology of NK cells has led to the development of promising therapeutic approaches. In this review, we will focus on the recent advances in NK cell immunobiology and the clinical application of NK cell immunotherapy in ovarian, cervical, and uterine cancer.

Original languageEnglish (US)
Article number1825
JournalFrontiers in immunology
Issue numberJAN
StatePublished - Jan 5 2018

Bibliographical note

Funding Information:
This work was supported by the following grants: NIH R35 CA197292 and U.S. Department of Defense CA150085, the Minnesota Ovarian Cancer Alliance (MOCA) (MG) "NK Cell Immunotherapy for Ovarian Cancer," Mayo Clinic Ovarian Cancer SPORE (P50 CA136393), and by a Research Scholar Grant (RSG-14-151-01-CCE) from the American Cancer Society.

Publisher Copyright:
© 2018 Uppendahl, Dahl, Miller, Felices and Geller.


  • Cervical cancer
  • Gynecologic malignancy
  • Immunotherapy
  • Natural killer cells
  • Ovarian cancer


Dive into the research topics of 'Natural killer cell-based immunotherapy in gynecologic malignancy: A review'. Together they form a unique fingerprint.

Cite this